S&P Equity Research downgrades Neurocrine Biosciences (Nasdaq: NBIX) from Hold to Sell.

S&P analyst, S. Silver, says, "Our ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE